What changed › 2026-09-03
NDA215866
Detected 2026-09-03 in the labels record for tirzepatide, by comparing that day’s fetch against the previous one.
What changed
| Change | Field | Value |
|---|---|---|
| field_changed | conditions | ['type-2-diabetes'] → ['cardiovascular-disease', 'type-2-diabetes'] |
| field_changed | indications | MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOU → MOUNJARO ® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to |
What the record says now
- Application
- NDA215866
- Brands
- Mounjaro, Mounjaro Kwikpen
- Label effective
- 2026-08-27
- Approved for
- cardiovascular disease, type 2 diabetes
See tirzepatide · the source record.
The previous value above is not recoverable from the source. Both ClinicalTrials.gov and the FDA revise records in place, keeping no public history, which is why this site keeps its own.